28
total announcements
ALIVUS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹16,550 Cr
P/E (TTM)
27.5
P/E (Forward)
21.5
EPS (TTM)
₹49.03
52W Low
₹819.00
52W High
₹1,493.80
Dividend Yield
0.37%
Beta
0.07
Price / Book
5.0
Debt / Equity
1.7
Revenue (TTM)
₹2,590 Cr
Gross Margin
59.42%
Operating Margin
29.84%
Alivus Life Sciences Limited
Alivus Life Sciences Limited has uploaded the audio recording of its Q1 FY2027 Earnings Call on its website, as per Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding the allotment of 32,000 Equity shares under the 'Employee Stock Option Scheme, 2021'. The paid-up share capital of the Company has increased to Rs. 24,55,42,896/-.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has reported Q1 FY27 results, with revenue growth of 6.4% YoY, driven by strong momentum in the non-GPL business, and EBITDA margins of 36.6%. The company expects revenue growth of 10-12% in FY27 and sustaining EBITDA margins in the 30-32% range.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced its financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 6,404 Mn, a growth of 6.4% YoY, driven by robust performance in the non-GPL business. EBITDA for Q1FY27 stood at Rs. 2,341 Mn, a growth of 29.1% YoY with margins at 36.6%, and PAT for Q1FY27 stood at Rs. 1,601 Mn, a growth of 31.8% YoY with margins at 25.0%. The company generated a strong free cash flow of Rs. 901 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 8,802 Mn as of June 30, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at Rs. 6,404.14 million, a 6% decrease from the previous quarter, and net profit for the period at Rs. 1,600.76 million.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has scheduled an earnings call for Q1 FY2026-27 on July 31, 2026, to discuss its financial performance.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of its Board Meeting on July 30, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited announced that institutional investors are scheduled to visit its plant in Ankleshwar, Gujarat, on June 29, 2026. This will be an in-person, group or one-on-one meeting. The disclosure is made pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Such interactions facilitate greater transparency and engagement with the investment community, allowing investors to gain direct insights into the company's operations and facilities.